Co-Diagnostics Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Webcast

Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX) will release its Q4 and full year 2025 financial results on Tuesday, March 31, 2026 after market close. A conference call and webcast to discuss results will be held the same day at 4:30 p.m. ET.

Management participants include Dwight Egan (CEO), Brian Brown (CFO) and Andrew Benson (Head of Investor Relations). The live webcast will be available at ir.co-dx.com and a replay will be posted on the company's website.

News Market Reaction – CODX

-8.40%

9 alerts

-8.40% News Effect

-8.2% Trough in 26 hr 13 min

-$465K Valuation Impact

$5M Market Cap

0.4x Rel. Volume

On the day this news was published, CODX declined 8.40%, reflecting a notable negative market reaction. Argus tracked a trough of -8.2% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $465K from the company's valuation, bringing the market cap to $5M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Earnings release date: March 31, 2026 Earnings call time: 4:30 p.m. ET Current price: $2.50 +5 more

8 metrics

Earnings release date March 31, 2026 Fourth quarter and full year 2025 results release after market close

Earnings call time 4:30 p.m. ET Conference call and webcast to discuss 2025 financial results

Current price $2.50 Price prior to earnings date announcement

1-day change -10.71% Move on the day reflected in market context

52-week high $46.50 Pre-news 52-week trading range high

52-week low $2.05 Pre-news 52-week trading range low

Toll-free call number 1-888-880-3330 Dial-in for earnings conference call

Toll call number 1-646-357-8766 Alternative dial-in for earnings conference call

Market Reality Check

Price: $2.65 Vol: Volume 182,439 vs 20-day ...

normal vol

$2.65 Last Close

Volume Volume 182,439 vs 20-day average 260,251 suggests activity below recent norms. normal

Technical Shares at $2.50 are trading below the $8.14 200-day moving average.

Peers on Argus

CODX is down 10.71% while momentum peers NXL, TNON, and INBS show gains between ...

3 Up

CODX is down 10.71% while momentum peers NXL, TNON, and INBS show gains between 3.25% and 4.05%, indicating stock-specific pressure rather than a sector-wide move.

Historical Context

5 past events · Latest: Mar 16 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 16	Conference participation	Positive	-10.0%	Participation at Medical Korea 2026 to present Co-Dx PCR platform.
Mar 12	Patent grant	Positive	-18.8%	Japanese patent with 34 claims covering Co-Dx PCR platform technologies.
Mar 10	Nasdaq compliance	Positive	+101.8%	Regained compliance with Nasdaq listing and $1.00 bid price rule.
Feb 09	Expo participation	Positive	-4.7%	Showcasing Co-Dx PCR platform at World Health Expo Labs Dubai.
Feb 05	Regulatory license	Positive	+0.0%	CoSara joint venture received CDSCO license for PCR Pro instrument.

Pattern Detected

Recent history shows frequent negative or flat reactions to generally positive operational updates, with the main exception being a strong move on Nasdaq compliance news.

Recent Company History

Over the last several months, CODX news has focused on commercialization progress and listing status. Events included a joint venture’s CDSCO license for the CoSara PCR Pro instrument on Feb 5, 2026, international showcasing of the Co-Dx PCR platform, and a Japanese patent grant with 34 claims on Mar 12, 2026. A key inflection was regaining Nasdaq compliance with the $1.00 bid rule on Mar 9, 2026, which drove a 101.83% move. By contrast, other positive updates often saw negative or muted price reactions.

Market Pulse Summary

The stock moved -8.4% in the session following this news. A negative reaction despite this being onl...

Analysis

The stock moved -8.4% in the session following this news. A negative reaction despite this being only an earnings date announcement fits CODX’s pattern of volatility around corporate events. Recent operational updates often saw negative or muted price responses, with declines of 10% and 18.83% following positive news. With shares far below the $46.50 52-week high and under the $8.14 200-day average, pre-earnings positioning and prior listing risk may have amplified downside moves.

Key Terms

molecular diagnostics

1 terms

molecular diagnostics medical

"a molecular diagnostics company with a unique, patented platform"

Molecular diagnostics are laboratory tests that look for specific molecules — such as genes, pieces of DNA or RNA, or proteins — to detect disease, predict risk, or guide treatment choices. For investors, these tests matter because they can change how illnesses are diagnosed and treated, create recurring revenue through specialized tests and companion products, and face clear regulatory and reimbursement pathways that drive commercial value; think of them as reading a biological barcode to inform medical decisions.

AI-generated analysis. Not financial advice.

SALT LAKE CITY, March 17, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced it will release its fourth quarter and full year 2025 financial results on Tuesday, March 31, 2026, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.

The conference call and webcast will be available via:

               Webcast: ir.co-dx.com on the Events & Webcasts page, or accessible directly here

               Conference Call: 1-888-880-3330 (Toll Free) or 1-646-357-8766 (Toll)

If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-announces-fourth-quarter-and-full-year-2025-earnings-release-date-and-webcast-302715625.html

SOURCE Co-Diagnostics

FAQ

When will Co-Diagnostics (CODX) release Q4 and full year 2025 results?

Co-Diagnostics will release Q4 and full year 2025 results on Tuesday, March 31, 2026, after market close. According to the company, management will discuss results on a conference call and webcast the same day at 4:30 p.m. ET for analysts and investors.

How can investors join the Co-Diagnostics (CODX) March 31, 2026 earnings webcast?

Investors can join the webcast at ir.co-dx.com on the Events & Webcasts page or via the direct webcast link. According to the company, the live stream will be available on its investor relations site and a replay will be posted afterward.

What phone numbers can be used to access the Co-Diagnostics (CODX) conference call?

Dial 1-888-880-3330 (toll free) or 1-646-357-8766 (toll) to access the conference call on March 31, 2026. According to the company, those numbers connect participants to the live call at 4:30 p.m. ET when management discusses results.

Who will represent Co-Diagnostics (CODX) on the March 31, 2026 earnings call?

Management on the call will include Dwight Egan (CEO), Brian Brown (CFO) and Andrew Benson (Head of Investor Relations). According to the company, these executives will discuss fourth quarter and full year 2025 financial results with analysts.

Will Co-Diagnostics (CODX) make a replay of the March 31, 2026 earnings call available?

Yes. The call will be recorded and later made available on the company's website for on-demand listening. According to the company, a replay will be posted on the investor relations site if you cannot participate live.

What time is the Co-Diagnostics (CODX) earnings call on March 31, 2026?

The earnings call is scheduled for 4:30 p.m. ET on Tuesday, March 31, 2026, immediately after the results release. According to the company, the webcast and call will follow the after-market announcement to review fourth quarter and full year 2025 results.